Leuprostin

Leuprorelin, the active ingredient in Leuprostin, is a GnRH agonist presented as an injectable solution for subcutaneous use. It is employed to suppress sex hormone production in conditions such as prostate cancer, breast cancer, endometriosis, uterine fibroids, and precocious puberty.

GNH USA supplies Leuprostin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Leuprostin, a GnRH agonist, is used in hormonal‑dependent conditions to reduce gonadotropin and sex‑steroid levels.

- Prostate cancer: lowers testosterone to inhibit tumor progression. - Breast cancer: suppresses estrogen production to support endocrine therapy. - Endometriosis: reduces pelvic estrogen to alleviate pain and lesion growth. - Uterine fibroids: diminishes estrogen stimulation, leading to fibroid shrinkage. - Precocious puberty: halts premature activation of the hypothalamic‑pituitary‑gonadal axis.

Leuprostin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes - Injection site pain or erythema - Headache - Fatigue - Mood swings - Decreased libido

Serious or Rare Side Effects: - Osteoporosis or decreased bone mineral density - Cardiovascular events such as myocardial infarction or stroke - Severe allergic reactions including anaphylaxis - Pituitary apoplexy (rare) - Significant depression or suicidal ideation - Elevated liver enzymes or hepatic dysfunction

Before initiating Leuprostin therapy, several precautions should be considered to ensure patient safety.

- Baseline hormone assessment: measure testosterone or estradiol levels to guide therapy. - Bone health monitoring: perform periodic densitometry to detect osteoporosis. - Cardiovascular risk evaluation: assess history of heart disease before treatment. - Hypersensitivity screening: avoid use in patients with known allergy to leuprorelin or formulation components. - Liver function review: monitor hepatic enzymes in patients with pre‑existing liver disease. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Leuprostin can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid): - Estrogen‑containing contraceptives: may reduce the suppressive effect of leuprorelin on gonadotropins. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower leuprorelin plasma concentrations. - Anticoagulants (e.g., warfarin): hormonal changes may affect coagulation status, requiring close monitoring.

Moderate Interactions (Monitor Closely): - Bisphosphonates or denosumab: concurrent use requires bone density monitoring. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of mood disturbances. - Thyroid hormone replacement: adjustments may be needed due to altered hormone metabolism. - Antidiabetic agents: changes in sex steroids can affect glucose control.